KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $147.6 million.

  • Adaptive Biotechnologies' Shares Outstanding (Weighted Average) rose 3.26% to $152.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.3 million, marking a year-over-year increase of 3.26%. This contributed to the annual value of $147.6 million for FY2024, which is 1.94% up from last year.
  • As of FY2024, Adaptive Biotechnologies' Shares Outstanding (Weighted Average) stood at $147.6 million, which was up 1.94% from $144.8 million recorded in FY2023.
  • Adaptive Biotechnologies' 5-year Shares Outstanding (Weighted Average) high stood at $147.6 million for FY2024, and its period low was $136.8 million during FY2020.
  • Over the past 3 years, Adaptive Biotechnologies' median Shares Outstanding (Weighted Average) value was $144.8 million (recorded in 2023), while the average stood at $145.1 million.
  • Data for Adaptive Biotechnologies' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 10.00% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' Shares Outstanding (Weighted Average) stood at $136.8 million in 2020, then increased by 3.19% to $141.1 million in 2021, then rose by 1.33% to $143.0 million in 2022, then rose by 1.23% to $144.8 million in 2023, then rose by 1.94% to $147.6 million in 2024.